CO5680441A2 - Combinaciones de un inhibidor de catepsina k y un bisfofonato en el tratamiento de metastasis osea, crecimiento de tumor y perdida osea inducida por tumor - Google Patents

Combinaciones de un inhibidor de catepsina k y un bisfofonato en el tratamiento de metastasis osea, crecimiento de tumor y perdida osea inducida por tumor

Info

Publication number
CO5680441A2
CO5680441A2 CO06016980A CO06016980A CO5680441A2 CO 5680441 A2 CO5680441 A2 CO 5680441A2 CO 06016980 A CO06016980 A CO 06016980A CO 06016980 A CO06016980 A CO 06016980A CO 5680441 A2 CO5680441 A2 CO 5680441A2
Authority
CO
Colombia
Prior art keywords
lower alkyl
aryl
osea
optionally substituted
bicycloalkyl
Prior art date
Application number
CO06016980A
Other languages
English (en)
Inventor
Johann Zimmermann
Carsten Goessl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5680441(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CO5680441A2 publication Critical patent/CO5680441A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

1.- Una preparación farmacéutica que comprende en combinación un bisfosfonato de fórmula I, o un éster fisiológicamente aceptable y dividible o una sal del mismo en donde X es hidrógeno, hidroxilo, amino, alcanoilo, o un grupo amino substituido por alquilo C1-C4, o alcanoilo R es hidrógeno o alquilo C1-C4 y Rx es una cadena lateral que contiene un grupo amino opcionalmente substituido, o un heterociclo que contiene nitrógeno (incluyendo heterociclos que contienen nitrógeno aromático), o una sal farmacéuticamente aceptable de los mismos o cualquier hidrato de los mismos; y a) un inhibidor de cat K de la fórmula V, o un éster fisiológicamente aceptable y dividible o una sal del mismoen donde R1 es opcionalmente substituido (arilo, aril-alquilo inferior, alquenilo inferior, alquinilo inferior, heterociclilo o heterociclil-alquilo inferior);R2 y R3 juntos representan alquileno inferior, opcionalmente interrumpido por O, S, o NR6, para formar un anillo con el átomo de carbono al cual se unen, y R6 es hidrógeno, alquilo inferior o arilalquilo inferior;R4 y R5 son independientemente H, u opcionalmente substituido (alquilo inferior o aril-alquilo inferior), -C(O)OR7, o -C(O)NR7R8, en donde R7 es opcionalmente substituido (alquilo inferior, arilo, aril-alquilo inferior, cicloalquilo, bicicloalquilo, bicicloalquilo o heterociclilo), y R8 es H, u opcionalmente substituido (alquilo inferior, arilo, aril-alquilo inferior, cicloalquilo, bicicloalquilo, bicicloalquilo o heterociclilo); o R4 y R5 juntos representan alquileno inferior, opcionalmente interrumpido por O, S o NR6, ...
CO06016980A 2003-07-21 2006-02-21 Combinaciones de un inhibidor de catepsina k y un bisfofonato en el tratamiento de metastasis osea, crecimiento de tumor y perdida osea inducida por tumor CO5680441A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48892503P 2003-07-21 2003-07-21

Publications (1)

Publication Number Publication Date
CO5680441A2 true CO5680441A2 (es) 2006-09-29

Family

ID=34135094

Family Applications (1)

Application Number Title Priority Date Filing Date
CO06016980A CO5680441A2 (es) 2003-07-21 2006-02-21 Combinaciones de un inhibidor de catepsina k y un bisfofonato en el tratamiento de metastasis osea, crecimiento de tumor y perdida osea inducida por tumor

Country Status (21)

Country Link
US (1) US20060281714A1 (es)
EP (1) EP1651238A1 (es)
JP (1) JP2006528151A (es)
KR (1) KR20060037382A (es)
CN (1) CN100406016C (es)
AR (1) AR045728A1 (es)
AU (1) AU2004262903B2 (es)
BR (1) BRPI0412769A (es)
CA (1) CA2532948A1 (es)
CO (1) CO5680441A2 (es)
EC (1) ECSP066293A (es)
IL (1) IL172913A0 (es)
IS (1) IS8311A (es)
MA (1) MA27925A1 (es)
MX (1) MXPA06000790A (es)
NO (1) NO20060851L (es)
PE (1) PE20050328A1 (es)
RU (1) RU2006105100A (es)
TN (1) TNSN06021A1 (es)
TW (1) TW200510436A (es)
WO (1) WO2005014006A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070135448A1 (en) * 2003-11-19 2007-06-14 Martin Missbach Use of cathepsin k inhibitors for treating of severe bone loss diseases
GB0427380D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
US20080219996A1 (en) * 2005-09-26 2008-09-11 Thea Kalebic Molecular Markers Associated with Bone Metastasis
US20100331545A1 (en) * 2007-10-24 2010-12-30 Nippon Chemiphar Co., Ltd. Regulator for signaling toll-like receptor, which comprises cathepsin inhibitor as active ingredient
US10590084B2 (en) 2016-03-09 2020-03-17 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
US11292801B2 (en) 2016-07-05 2022-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
CA3038331A1 (en) 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
US20210298890A1 (en) 2018-06-27 2021-09-30 Cirlo Gmbh Implants for recruiting and removing circulating tumor cells
WO2021122803A2 (en) 2019-12-17 2021-06-24 Cirlo Gmbh Tubular shaped elongated catheter device assemblies for interacting with components of bodily fluids, method for recovering cells, cell aggregates and exosomes from a tubular shaped elongated catheter device and smart tubular shaped elongated catheter device assemblies for monitoring interaction with components of bodily fluids
WO2023212104A1 (en) * 2022-04-27 2023-11-02 The Regents Of The University Of California Methods and agents for preventing skeletal aging, osteoporosis and obesity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5501969A (en) * 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
US6544767B1 (en) * 1994-10-27 2003-04-08 Axys Pharmaceuticals, Inc. Cathespin O2 protease
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
JP2002521450A (ja) * 1998-07-29 2002-07-16 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
JP2002539190A (ja) * 1999-03-15 2002-11-19 アクシス・ファーマシューティカルズ・インコーポレイテッド プロテアーゼ阻害剤としての新規化合物および組成物
DE60019580T2 (de) * 1999-05-21 2006-03-09 Novartis Ag Verwendung von biphosphonsäuren zur behandlung von angiogenese
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
CA2466115A1 (en) * 2001-11-13 2003-05-22 Merck Frosst Canada & Co./Merck Frosst Canada & Cie Cyanoalkylamino derivatives as protease inhibitors

Also Published As

Publication number Publication date
AU2004262903A1 (en) 2005-02-17
MA27925A1 (fr) 2006-06-01
US20060281714A1 (en) 2006-12-14
IL172913A0 (en) 2006-06-11
CA2532948A1 (en) 2005-02-17
IS8311A (is) 2006-02-17
PE20050328A1 (es) 2005-06-16
MXPA06000790A (es) 2006-04-07
ECSP066293A (es) 2006-07-28
AU2004262903B2 (en) 2007-08-23
CN1826124A (zh) 2006-08-30
BRPI0412769A (pt) 2006-09-26
AR045728A1 (es) 2005-11-09
TNSN06021A1 (en) 2007-10-03
NO20060851L (no) 2006-04-21
JP2006528151A (ja) 2006-12-14
RU2006105100A (ru) 2007-09-20
EP1651238A1 (en) 2006-05-03
WO2005014006A1 (en) 2005-02-17
CN100406016C (zh) 2008-07-30
KR20060037382A (ko) 2006-05-03
TW200510436A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
CO5680441A2 (es) Combinaciones de un inhibidor de catepsina k y un bisfofonato en el tratamiento de metastasis osea, crecimiento de tumor y perdida osea inducida por tumor
PE20190705A1 (es) COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING
PE20140411A1 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
PA8501801A1 (es) Inhibidores triciclicos de polimerasas (adp - polirribosas)
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
PE20060842A1 (es) Amino-imidazolonas para la inhibicion de b-secretasa
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
PA8490601A1 (es) Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos.
AR049399A1 (es) Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos
MX2010004312A (es) Derivados de 1,3,4-tiadiazol espiro-condensados para inhibir la actividad de quinesina de la proteina de quinesina del huso.
CO5700767A2 (es) Procedimiento de tratamiento de rechazo de transplantes
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
SV2002000504A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal ref.pc10760/20205/bb
AR067562A1 (es) Compuestos heterociclicos inhibidores de kinasa
UY28564A1 (es) Compuestos quimicos
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
AR065439A1 (es) Derivados de tiazoles 1,3 no condensados,composiciones farmaceuticas que los contienen y usos como agentes antivirales, en particular anti hiv.
UY28132A1 (es) Derivados de pirrolopirimidina
PA8638101A1 (es) Inhibidores de cetp
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
AR067904A1 (es) Derivados de piperazina-amida
PE20080144A1 (es) Compuestos de tetrahidropiridotienopirimidina con actividad antiproliferativa
RU2008116674A (ru) Новые циклические пептидные соединения
AR065863A1 (es) Derivados de imidazolidinona

Legal Events

Date Code Title Description
FA Application withdrawn